dopamine

Class

dopaminergic stabilizer

Dopamine is a neurotransmitter that relays signals in circuits controlling voluntary movement, motivation, and reward. In Parkinson's disease, the neurons that produce dopamine in the substantia nigra progressively degenerate, leaving the striatum, a brain region central to motor control, with insufficient dopaminergic tone. This produces tremor, rigidity, slowed movement, and postural instability. One therapeutic strategy is to directly stimulate the dopamine receptors that these degenerating neurons would normally activate, bypassing the need for endogenous dopamine synthesis. Small-molecule dopamine receptor agonists bind the same receptors as dopamine itself and can restore a level of signaling sufficient to improve motor symptoms. Because dopamine has a very short half-life and Parkinson's disease requires sustained receptor engagement, agonists are formulated in varied ways: rapid-onset injectable or sublingual forms for acute relief of sudden immobility episodes, and long-acting oral, extended-release, or transdermal patch formulations intended to provide steadier receptor stimulation across the day. This mechanism is relevant not only in Parkinson's disease but also in restless legs syndrome, another condition linked to disrupted dopaminergic signaling. The broad principle, replacing lost or deficient dopaminergic drive by acting directly at the receptor, underlies most pharmacological approaches to managing these movement disorders.